Edward Chung - Head, Investor Relations Andy Last - Executive Vice President and Chief Operating Officer Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Ilan Daskal - Executive Vice President and Chief Financial Officer Tim Daley - Wells Fargo Brandon Couillard - Jefferies Edward Chung Good afternoon, everyone and thank you for joining us. Today, we will review the second quarter 2023 financial r ...

Common Shares Outstanding at July 28, 2023: Class A - 24,004,023 Class B - 5,072,204 BIO-RAD LABORATORIES, INC. Condensed Consolidated Balance Sheets (continued) (In thousands, except share data) | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------------------|----- ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Ed Chung - Vice President, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citi Dan L ...

Available-for-sale investments consist of the following (in millions): March 31, 2023 17 The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2023 by contractual maturity date (in millions): 38 We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and during the three months ended March 31, 2023 our foreign entities generated 56% of our net sales. Compliance with complex fore ...

Company Participants Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET Edward Chung - Vice President, Investor Relations Norman Schwartz - President and Chief Executive Officer Patrick Donnelly - Citigroup Inc. Jack Meehan - Nephron Research LLC I would now like to pass the conference over to your host, Edward Chung with Bio-Rad. Please proceed. Edward Chung With me on the call today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year endedDecember 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charte ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Dara Wright - EVP & President, Clinical Diagnostics Group Simon May - EVP & President, the Life Science Group Conference Call Participants Patrick Donnelly - Citigroup Brandon Couillard - Jefferies Daniel Leonard - Crédit Suisse Jack Meehan - Nephron Research Operator Good even ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-138 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 6:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President of Life Science Group Dara Wright - President of Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Good afternoon. Thank you for atte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...